Review Early View

Autoantibody Repertoire in Rheumatoid Arthritis: Advances, Challenges, and Clinical Perspectives

Publish Date: September 16, 2026
Full Text PDF
DOI
Lu He ORCID
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China image/svg+xml
Qinghui Luo ORCID
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China image/svg+xml
Jie Yan ORCID
Department of Clinical Laboratory image/svg+xml
Faquan Lin ORCID
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China image/svg+xml
He, L., Luo, Q., Yan, J., & Lin, F. (2026). Autoantibody Repertoire in Rheumatoid Arthritis: Advances, Challenges, and Clinical Perspectives. Archives of Rheumatology. https://doi.org/10.5152/ArchRheumatol.2026.26410
Full Text Full Text PDF

Abstract

This narrative review summarizes current evidence on the autoantibody repertoire in rheumatoid arthritis (RA) and its clinical relevance. Autoantibody testing remains central to diagnosis and disease classification, with rheumatoid factor (RF) and antibodies to citrullinated proteins representing the most widely used serological markers. However, these conventional biomarkers do not fully capture the heterogeneity of the disease, and a substantial proportion of patients remain seronegative. In recent years, several emerging autoantibodies, including anti-carbamylated protein antibodies, anti-peptidylarginine deiminase 4 antibodies, anti-RA33, and anti-14-3-3η, have shown potential value as complementary biomarkers, particularly in early or seronegative disease. Some autoantibodies may also be detectable before the onset of clinically apparent arthritis, supporting a possible role in risk assessment and disease stratification. At the same time, their broader clinical application remains limited by assay heterogeneity, non-uniform diagnostic thresholds, and insufficient prospective validation. Overall, established and emerging autoantibodies provide important insight into diagnosis and disease subsets in RA, but further standardization is needed before wider clinical implementation.

Cite this article as: He L, Luo Q, Yan J, Lin F. Autoantibody Repertoire in Rheumatoid Arthritis: Advances, Challenges, and Clinical Perspectives. ArchRheumatol. Published online September 16, 2026. doi: 10.5152/ArchRheumatol.2026.26410.

Similar Articles

Article Info
Published In
Journal Archives of Rheumatology
History
Published Online September 16, 2026
License
Affiliations
Lu He ORCID
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China
Qinghui Luo ORCID
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China
Jie Yan ORCID
Department of Clinical Laboratory
Faquan Lin ORCID
Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Medical University, Education Department of Guangxi Zhuang Autonomous Region, Guangxi, China
Cite this Article
He, L., Luo, Q., Yan, J., & Lin, F. (2026). Autoantibody Repertoire in Rheumatoid Arthritis: Advances, Challenges, and Clinical Perspectives. Archives of Rheumatology. https://doi.org/10.5152/ArchRheumatol.2026.26410
Share
Outlines